PD-1 Antibody and Lenvatinib Plus TACE on Downstaging BCLC B/C HCC
2022年8月16日 更新者:Lunxiu Qin、Fudan University
Efficacy and Safety of PD-1 Antibody and Lenvatinib Plus TACE on Downstaging Hepatocellular Carcinoma With BCLC B/C
The purpose of this study is to assess the difference of safety and efficacy about PD-1 Antibody and Lenvatinib Plus transcatheter arterial chemoembolization (TACE) on downstaging hepatocellular carcinoma with BCLC B/C.
研究概览
研究类型
介入性
注册 (预期的)
50
阶段
- 第一阶段早期
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习联系方式
- 姓名:Lunxiu Qin, M.D
- 电话号码:+862152887172
- 邮箱:qinlx99@163.com
学习地点
-
-
Shanghai
-
Shanghai、Shanghai、中国、200040
- 招聘中
- Huashan Hospital
-
接触:
- Ying Zhu, Ph.D
- 电话号码:+862152887175
- 邮箱:yzhu14@fudan.edu.cn
-
接触:
- Lu Lu, M.D
- 电话号码:+862152887174
- 邮箱:lulu@huashan.org.cn
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
18年 至 75年 (成人、年长者)
接受健康志愿者
不
有资格学习的性别
全部
描述
Inclusion Criteria:
- Age ≥18 years old and ≤75 years old;
- Clinically diagnosed as hepatocellular carcinoma, stage B/C of BCLC;
- No history of severe arrhythmia or heart failure;
- No history of severe ventilation dysfunction or severe pulmonary infection;
- No acute or chronic renal failure, the creatinine clearance rate was >40 mL/min;
- Liver function Child A;
- Blood routine: absolute neutrophils count ≥1.5×10^9/L, Hb≥8.5g/L, PLT≥75×10^9/L;
- Coagulation function: INR≤2.3;
- ECOG score <2;
- No local or systemic treatment, such as TACE, RFA, targeted drugs, traditional Chinese medicine, etc., before enrollment;
- Expected survival ≥12 weeks;
- At least one lesion can be measured and evaluated by CT/MRI according to RECIST 1.1 criteria;
- Understand and sign the informed consent.
Exclusion Criteria:
- Pregnant or lactating women;
- Patients with other malignant tumors;
- patients with complicated mental illness;
- patients who have participated in other clinical trials in the last three months;
- known or suspected allergy to any drug related to the study;
- Patients with positive immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS)
- Patients treated with other targeted drugs, PD-L1 antibody and other immunotherapy or FOLFOX systemic chemotherapy after inclusion;
- Patients with ≥1 + proteinuria indicated by urine routine will receive 24-hour urine protein detection, and patients with ≥1g 24-hour urine protein will not be included in the group.
- Active autoimmune diseases that require systemic treatment (use of disease-alleviating agents, such as corticosteroids or immunosuppressants)
- Patients with uncontrolled hepatitis B/C infection
- Other conditions that the researcher considers not suitable for inclusion in this study
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
其他:PD-1+TACE+Len
PD-1 Antibody and Lenvatinib Plus TACE
|
PD-1 Antibody and Lenvatinib Plus Transarterial chemoembolization(TACE ): Patients were recommended to receive TACE once every 6 weeks.
Patients were recommended to begin oral administration of Lenvatinib 3 days after the first TACE treatment, and meanwhile to start intravenous drip of PD-1 antibody 3 days after the first TACE treatment, once every 3 weeks.
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Resection rate
大体时间:6 months after downstaging treatment
|
Resction rate refers to the proportion of patients who can receive radical surgery after downstaging treatment.
|
6 months after downstaging treatment
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Adverse events (safety)
大体时间:6 months
|
Postoperative adverse events (safety ) will be evaluated according to the NCI CTCAE Version 4.03.The number and severity of treatment-related side effects, including AE and SAE, will be recorded during treatment.
|
6 months
|
|
Overall survival (OS)
大体时间:2 years
|
The duration from the date of recruitment to the date of death from any cause.
|
2 years
|
|
Objective response rate (ORR)
大体时间:6 months
|
ORR is defined as the percentage of participants who have a confirmed complete response or partial response according to RECIST 1.1 or mRECIST.
|
6 months
|
|
Progression free survival (PFS)
大体时间:6 months
|
PFS is defined as the time from enrollment of the trial to the first documented disease progression or death due to any cause.
|
6 months
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
调查人员
- 研究主任:Lunxiu Qin, M.D、Department of Surgery, Huashan Hospital, Fudan University
出版物和有用的链接
负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。
一般刊物
- Kudo M, Finn RS, Qin S, Han KH, Ikeda K, Piscaglia F, Baron A, Park JW, Han G, Jassem J, Blanc JF, Vogel A, Komov D, Evans TRJ, Lopez C, Dutcus C, Guo M, Saito K, Kraljevic S, Tamai T, Ren M, Cheng AL. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial. Lancet. 2018 Mar 24;391(10126):1163-1173. doi: 10.1016/S0140-6736(18)30207-1.
- Kato Y, Tabata K, Kimura T, Yachie-Kinoshita A, Ozawa Y, Yamada K, Ito J, Tachino S, Hori Y, Matsuki M, Matsuoka Y, Ghosh S, Kitano H, Nomoto K, Matsui J, Funahashi Y. Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway. PLoS One. 2019 Feb 27;14(2):e0212513. doi: 10.1371/journal.pone.0212513. eCollection 2019.
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018 Nov;68(6):394-424. doi: 10.3322/caac.21492. Epub 2018 Sep 12. Erratum In: CA Cancer J Clin. 2020 Jul;70(4):313.
- Lencioni R, de Baere T, Soulen MC, Rilling WS, Geschwind JF. Lipiodol transarterial chemoembolization for hepatocellular carcinoma: A systematic review of efficacy and safety data. Hepatology. 2016 Jul;64(1):106-16. doi: 10.1002/hep.28453. Epub 2016 Mar 7.
- Kudo M, Ueshima K, Ikeda M, Torimura T, Tanabe N, Aikata H, Izumi N, Yamasaki T, Nojiri S, Hino K, Tsumura H, Kuzuya T, Isoda N, Yasui K, Aino H, Ido A, Kawabe N, Nakao K, Wada Y, Yokosuka O, Yoshimura K, Okusaka T, Furuse J, Kokudo N, Okita K, Johnson PJ, Arai Y; TACTICS study group. Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. Gut. 2020 Aug;69(8):1492-1501. doi: 10.1136/gutjnl-2019-318934. Epub 2019 Dec 4.
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (实际的)
2021年1月1日
初级完成 (预期的)
2022年12月31日
研究完成 (预期的)
2022年12月31日
研究注册日期
首次提交
2021年6月20日
首先提交符合 QC 标准的
2021年7月13日
首次发布 (实际的)
2021年7月23日
研究记录更新
最后更新发布 (实际的)
2022年8月18日
上次提交的符合 QC 标准的更新
2022年8月16日
最后验证
2022年8月1日
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.